Evidence map›Paper›PMID 41914368›Full record

ReviewChemical record (New York, N.Y.)2026

Design Strategies for Compact Photoluminescent Liquid Crystals Based on Fluorinated Tolane Frameworks.

Shigeyuki Yamada, Motohiro Yasui, Tsutomu Konno

Abstract readReview
In one paragraph

Review in Chemical record (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shigeyuki YamadaFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6379-0447
Motohiro YasuiFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.ORCID https://orcid.org/0000-0001-9324-3463
Tsutomu KonnoFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.ORCID https://orcid.org/0000-0002-5146-9840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluorinated tolane derivatives offer rigid and compact π-conjugated frameworks in which electronic structure and intermolecular interactions can be precisely modulated, making them attractive platforms for integrating mesomorphic order and photoluminescence within a single molecular architecture. In this account, we summarize our systematic efforts to establish molecular design strategies for compact fluorinated tolane-based photoluminescent liquid crystals (PLLCs), with a particular focus on controlling molecular aggregation across crystalline and liquid-crystalline phases. Three complementary design approaches are discussed: molecular dimerization to reduce crystallinity and induce mesomorphism, partial fluorination combined with semifluoroalkoxy chains to balance electronic effects and aggregation moedes, and ionic functionalization using imidazolium termini to induce dynamic layered order and counteranion-dependent control. Though these strategies, the roles of fluorination, spacer length, flexible chains, and ionic interactions in governing mesophase stability and solid-state photoluminescence are elucidated. Collectively, these studies demonstrate how hierarchical control of molecular order enables the reconciliation of mesomorphic behavior and efficient emission within compact π-conjugated systems, and they provide general design principles for the development of responsive emissive soft materials.

Indexed as

donor–π–acceptor architecturefluorinated π‐conjugated materialsmesophase stabilizationmolecular design strategyphotoluminescent liquid crystals

Identifiers

PMID41914368
PMCPMC13184814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.